CBKM120ZUS40: Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - BKM120 for Patients with PI3K-activated Tumors
To find out if BKM120 (the study drug) is safe and has beneficial effects in people with different kinds of cancer.
Solid tumors (except endometrial cancer, glioblastoma, non-small cell lung cancer, prostate cancer, and breast cancer) and blood cancers (including diffuse large B cell lymphoma and multiple myeloma).
1. Male or female at least 18 years old.
2. Confirmed diagnosis of select solid tumor or blood cancer.
3. Known to have a PI3K pathway activation (a specific mutation in the tumor).
4. Received at least one prior treatment for recurrent, metastatic, and/or locally advanced disease.
5. Other criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until your disease gets worse or you develop unacceptable side effects.
Knight Clinical Trials Information Line